Meeting
2017 ASCO Annual Meeting
Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.
Authors
Nathan Hale Fowler
The University of Texas MD Anderson Cancer Center, Houston, TX
Nathan Hale Fowler , Sattva Swarup Neelapu , Felipe Samaniego , Sheryl Forbes , Fredrick B. Hagemeister Jr., Luis Fayad , Lei Feng , Francesco Turturro , Jason R. Westin , Janine Arafat , Eleanor Neal , Loretta J. Nastoupil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT01995669
Citation
J Clin Oncol 35, 2017 (suppl; abstr 7531)
DOI
10.1200/JCO.2017.35.15_suppl.7531
Abstract #
7531
Poster Bd #
293
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial.
First Author: Pier Luigi Zinzani
Poster
2022 ASCO Annual Meeting
Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
First Author: Lorenzo Falchi
Poster
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
First Author: Hua-Jay Jeffery Cherng
Poster
2013 ASCO Annual Meeting
A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM).
First Author: James D. Hilger